At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 20 target
Drug / intervention
DMMET-01 +1 moredrug
Likely dose
DMMET-01 1050.6 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized, Double-Blind, Efficacy and Safety, Controlled Study, Between DMMET-01 and Metformin on Improvement of Metabolic Control in Naive Type 2 Diabetics Patients.
In Brief
A Phase 3 clinical trial evaluating DMMET-01 and Metformin Hydrochloride for Diabetes Type 2. Completed, enrolled 20 participants across 1 site.
Detailed Summary
The aim of this clinical trial is to compare the efficacy of DMMET-01 versus metformin hydrocloride on metabolic control in mexican type 2 diabetes patients without prior pharmacological treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Type 2
CountriesMexico
Collaborators--
Timeline
Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMar 2009
First PostedJul 2009
Primary CompletionDec 2009
TodayJul 2026
First PostedJul 16, 2009
Enrollment StartMar 1, 2009
Primary CompletionDec 1, 2009
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 17.0 years ago
Interventions
DMMET-01drug
90 days: 15 days daily dose 1050.6 mg (before dinner)+75 days dose twice a day 1050.6 mg (before breakfast) 1050.6 mg (before dinner).
Metformin Hydrochloridedrug
90 days: 15 days daily dose 850 mg (before dinner)+ 75 days dose twice a day 850 mg (before breakfast) 850 mg (before dinner)